Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Aug;24(2):141–144. doi: 10.1128/aac.24.2.141

Multiple-dose pharmacokinetics of ceftazidime in cancer patients.

I Garcia, V Fainstein, R G Smith, G P Bodey
PMCID: PMC185126  PMID: 6357067

Abstract

The pharmacokinetic parameters of ceftazidime were determined in 25 patients with neoplastic diseases. A group of 13 patients each received 1 g of ceftazidime over 15 min as a single intravenous dose. The mean peak drug concentration in serum was 77.4 micrograms/ml, and the serum half-life was 144 min. Urinary excretion at 12 h was 64.5%. These 13 patients also received 2 g of ceftazidime over 15 min at 8-h intervals for 7 or 8 days. The mean peak drug concentrations in serum were 103.6 micrograms/ml on day 1 and 87 micrograms/ml on day 7 or 8. A second group of 12 patients received 1 g of ceftazidime over 30 min, followed by 1 g over 2 h and every 4 h thereafter. The mean peak drug concentration in serum at 30 min was 57.5 micrograms/ml. Average peak and trough levels obtained on day 2 or 3 were 65 and 34.8 micrograms/ml, respectively, and remained in this range thereafter. The above-mentioned dose schedules produced high and adequate ceftazidime concentrations in serum.

Full text

PDF
141

Images in this article

142Image
on p.142

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Fainstein V., Hinkle A. M. Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother. 1981 Aug;20(2):226–230. doi: 10.1128/aac.20.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodey G. P., Valdivieso M., Yap B. S. The role of schedule of antibiotic therapy on the neutropenic patient. Infection. 1980;Suppl 1:75–81. doi: 10.1007/BF01644940. [DOI] [PubMed] [Google Scholar]
  3. Brogard J. M., Comte F., Pinget M. Pharmacokinetics of cephalosporin antibiotics. Antibiot Chemother (1971) 1978;25:123–162. doi: 10.1159/000401060. [DOI] [PubMed] [Google Scholar]
  4. Estey E. H., Weaver S. S., Ho D. H., Bodey G. P. Clinical pharmacology of moxalactam in patients with malignant disease. Antimicrob Agents Chemother. 1981 Apr;19(4):639–644. doi: 10.1128/aac.19.4.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fu K. P., Aswapokee P., Ho I., Matthijssen C., Neu H. C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother. 1979 Nov;16(5):592–597. doi: 10.1128/aac.16.5.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Geddes A. M. Antibiotics and travellers' diarrhoea. J Antimicrob Chemother. 1981 Oct;8(4):247–248. doi: 10.1093/jac/8.4.247. [DOI] [PubMed] [Google Scholar]
  7. King A., Warren C., Shannon K., Phillips I. In-vitro antibacterial activity of cefoperazone, a piperazine cephalosporin. J Antimicrob Chemother. 1981 Aug;8(2):107–113. doi: 10.1093/jac/8.2.107. [DOI] [PubMed] [Google Scholar]
  8. Seddon M., Wise R., Gillett A. P., Livingston R. Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980 Aug;18(2):240–242. doi: 10.1128/aac.18.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Tanphaichitra D., Bussayanond A., Christensen O. The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever. J Antimicrob Chemother. 1981 Jul;8(1):23–28. doi: 10.1093/jac/8.1.23. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES